Idraparinux versus standard therapy for venous thromboembolic disease.

Antithrombotic therapy for VTE disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest (2012) 10.75

A pharmacogenetic versus a clinical algorithm for warfarin dosing. N Engl J Med (2013) 7.09

Factor XI antisense oligonucleotide for prevention of venous thrombosis. N Engl J Med (2014) 4.58

Lessons learned from the contamination of heparin. Nat Prod Rep (2009) 2.81

Oral rivaroxaban versus standard therapy for the treatment of symptomatic venous thromboembolism: a pooled analysis of the EINSTEIN-DVT and PE randomized studies. Thromb J (2013) 2.21

Sulodexide for the Prevention of Recurrent Venous Thromboembolism: The Sulodexide in Secondary Prevention of Recurrent Deep Vein Thrombosis (SURVET) Study: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial. Circulation (2015) 2.01

New antithrombotic drugs: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest (2012) 1.59

Clinical trials in peripheral vascular disease: pipeline and trial designs: an evaluation of the ClinicalTrials.gov database. Circulation (2014) 1.44

The discovery and development of rivaroxaban, an oral, direct factor Xa inhibitor. Nat Rev Drug Discov (2010) 1.33

Rivaroxaban and other novel oral anticoagulants: pharmacokinetics in healthy subjects, specific patient populations and relevance of coagulation monitoring. Thromb J (2013) 1.15

Rationale and design of the Clarification of Optimal Anticoagulation through Genetics trial. Am Heart J (2013) 1.12

New anticoagulants: how to deal with treatment failure and bleeding complications. Br J Clin Pharmacol (2011) 1.11

Characterization of the plasma and blood anticoagulant potential of structurally and mechanistically novel oligomers of 4-hydroxycinnamic acids. Blood Coagul Fibrinolysis (2009) 1.10

Use of anticoagulants in elderly patients: practical recommendations. Clin Interv Aging (2009) 1.04

Benchmark for time in therapeutic range in venous thromboembolism: a systematic review and meta-analysis. PLoS One (2012) 0.96

Prophylactic and therapeutic anticoagulation for thrombosis: major issues in oncology. Nat Clin Pract Oncol (2008) 0.87

Clinical evidence for rebound hypercoagulability after discontinuing oral anticoagulants for venous thromboembolism. Medscape J Med (2008) 0.86

Phase III trials of new oral anticoagulants in the acute treatment and secondary prevention of VTE: comparison and critique of study methodology and results. Adv Ther (2014) 0.85

Clinical use of rivaroxaban: pharmacokinetic and pharmacodynamic rationale for dosing regimens in different indications. Drugs (2014) 0.83

New oral anticoagulants for the treatment of venous thromboembolism: understanding differences and similarities. Drugs (2014) 0.82

Respiratory review of 2013: pulmonary thromboembolism. Tuberc Respir Dis (Seoul) (2013) 0.82

Pharmacokinetic and pharmacodynamic evaluation of rivaroxaban: considerations for the treatment of venous thromboembolism. Thromb J (2014) 0.81

Rivaroxaban for the treatment of pulmonary embolism. Adv Ther (2013) 0.81

Rivaroxaban versus enoxaparin/vitamin K antagonist therapy in patients with venous thromboembolism and renal impairment. Thromb J (2014) 0.79

Rivaroxaban and other non-vitamin K antagonist oral anticoagulants in the emergency treatment of thromboembolism. Int J Emerg Med (2013) 0.78

Treatment of venous thromboembolism - effects of different therapeutic strategies on bleeding and recurrence rates and considerations for future anticoagulant management. Thromb J (2012) 0.78

Anticoagulant effects of idraparinux after termination of therapy for prevention of recurrent venous thromboembolism: observations from the van Gogh trials. Eur J Clin Pharmacol (2008) 0.77

Direct oral anticoagulants in the treatment of venous thromboembolism, with a focus on patients with pulmonary embolism: an evidence-based review. Vasc Health Risk Manag (2014) 0.77

Measures of vitamin K antagonist control reported in atrial fibrillation and venous thromboembolism studies: a systematic review. BMJ Open (2014) 0.76

Potential role of new anticoagulants for prevention and treatment of venous thromboembolism in cancer patients. Vasc Health Risk Manag (2013) 0.76

Inhibitors of propagation of coagulation: factors V and X. Br J Clin Pharmacol (2011) 0.76

Evidence-Based Development and Rationale for Once-Daily Rivaroxaban Dosing Regimens Across Multiple Indications. Clin Appl Thromb Hemost (2016) 0.75

ACP Journal Club. Enoxaparin plus idrabiotaparinux was noninferior to enoxaparin plus warfarin for recurrent VTE in acute PE. Ann Intern Med (2012) 0.75

Commentary. Idraparinux versus standard therapy for venous thromboembolic disease. Extended prophylaxis of venous thromboembolism with idraparinux. Perspect Vasc Surg Endovasc Ther (2008) 0.75

Advantages of a Warfarin Protocol for Long-term Care Pharmacists: a Retrospective Cohort Study. Can Geriatr J (2016) 0.75

Sample Size Estimation for Non-Inferiority Trials: Frequentist Approach versus Decision Theory Approach. PLoS One (2015) 0.75

Idraparinux was noninferior to standard therapy for deep venous thrombosis but inferior for pulmonary embolism. ACP J Club (2008) 0.75

Role of factor xa inhibitors in cancer-associated thrombosis: any new data? Adv Hematol (2011) 0.75

Bioequipotency of idraparinux and idrabiotaparinux after once weekly dosing in healthy volunteers and patients treated for acute deep vein thrombosis. Br J Clin Pharmacol (2013) 0.75

Idraparinux or idrabiotaparinux for long-term venous thromboembolism treatment: a systematic review and meta-analysis of randomized controlled trials. PLoS One (2013) 0.75

New prospective for the management of low-risk pulmonary embolism: prognostic assessment, early discharge, and single-drug therapy with new oral anticoagulants. Scientifica (Cairo) (2012) 0.75

Novel Anticoagulant Therapy of Venous Thromboembolism: Current Status and Future Directions. Ann Vasc Dis (2017) 0.75

The accuracy of combined use of troponin and red cell distribution width in predicting mortality of patients with acute pulmonary embolism. Wien Klin Wochenschr (2016) 0.75

Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. N Engl J Med (2012) 11.86

Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. N Engl J Med (2003) 11.00

Prophylactic use of an implantable cardioverter-defibrillator after acute myocardial infarction. N Engl J Med (2004) 10.02

Oral rivaroxaban for symptomatic venous thromboembolism. N Engl J Med (2010) 9.92

Comparison of low-intensity warfarin therapy with conventional-intensity warfarin therapy for long-term prevention of recurrent venous thromboembolism. N Engl J Med (2003) 8.55

Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism. N Engl J Med (2013) 7.76

The diagnostic odds ratio: a single indicator of test performance. J Clin Epidemiol (2003) 7.54

Antithrombotic therapy for venous thromboembolic disease: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest (2008) 7.12

Oral apixaban for the treatment of acute venous thromboembolism. N Engl J Med (2013) 7.00

Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty (RECORD4): a randomised trial. Lancet (2009) 6.83

A comparison of two intensities of warfarin for the prevention of recurrent thrombosis in patients with the antiphospholipid antibody syndrome. N Engl J Med (2003) 6.57

Reversal of rivaroxaban and dabigatran by prothrombin complex concentrate: a randomized, placebo-controlled, crossover study in healthy subjects. Circulation (2011) 6.47

Antithrombotic therapy for venous thromboembolic disease: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest (2004) 5.96

Comparison of fixed-dose weight-adjusted unfractionated heparin and low-molecular-weight heparin for acute treatment of venous thromboembolism. JAMA (2006) 5.69

Incidence of chronic thromboembolic pulmonary hypertension after pulmonary embolism. N Engl J Med (2004) 5.68

Apixaban versus enoxaparin for thromboprophylaxis after hip replacement. N Engl J Med (2010) 5.59

Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement: a randomised, double-blind, non-inferiority trial. Lancet (2007) 5.41

Effectiveness of managing suspected pulmonary embolism using an algorithm combining clinical probability, D-dimer testing, and computed tomography. JAMA (2006) 4.75

Factor XI antisense oligonucleotide for prevention of venous thrombosis. N Engl J Med (2014) 4.58

Fondaparinux or enoxaparin for the initial treatment of symptomatic deep venous thrombosis: a randomized trial. Ann Intern Med (2004) 4.52

Atrial fibrillation management: a prospective survey in ESC member countries: the Euro Heart Survey on Atrial Fibrillation. Eur Heart J (2005) 4.46

Apixaban for extended treatment of venous thromboembolism. N Engl J Med (2012) 4.37

Residual thrombosis on ultrasonography to guide the duration of anticoagulation in patients with deep venous thrombosis: a randomized trial. Ann Intern Med (2009) 4.27

Pulmonary arterial hypertension: baseline characteristics from the REVEAL Registry. Chest (2009) 4.08

Pacemaker therapy for prevention of syncope in patients with recurrent severe vasovagal syncope: Second Vasovagal Pacemaker Study (VPS II): a randomized trial. JAMA (2003) 3.93

ADAMTS13 activity in thrombotic thrombocytopenic purpura-hemolytic uremic syndrome: relation to presenting features and clinical outcomes in a prospective cohort of 142 patients. Blood (2003) 3.88

Comparison of beta-blockers, amiodarone plus beta-blockers, or sotalol for prevention of shocks from implantable cardioverter defibrillators: the OPTIC Study: a randomized trial. JAMA (2006) 3.84

Below-knee elastic compression stockings to prevent the post-thrombotic syndrome: a randomized, controlled trial. Ann Intern Med (2004) 3.74

Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis. Blood (2002) 3.59

Efficacy and safety of fondaparinux for the prevention of venous thromboembolism in older acute medical patients: randomised placebo controlled trial. BMJ (2006) 3.58

Residual venous thrombosis as a predictive factor of recurrent venous thromboembolism. Ann Intern Med (2002) 3.51

Randomized comparison of low molecular weight heparin and coumarin derivatives on the survival of patients with cancer and venous thromboembolism. J Clin Oncol (2005) 3.42

An association between atherosclerosis and venous thrombosis. N Engl J Med (2003) 3.39

Apixaban versus enoxaparin for thromboprophylaxis after knee replacement (ADVANCE-2): a randomised double-blind trial. Lancet (2010) 3.29

The changing picture of patients with pulmonary arterial hypertension in the United States: how REVEAL differs from historic and non-US Contemporary Registries. Chest (2010) 3.02

Left bundle-branch block induced by transcatheter aortic valve implantation increases risk of death. Circulation (2012) 2.95

Apixaban or enoxaparin for thromboprophylaxis after knee replacement. N Engl J Med (2009) 2.90

Human embryonic stem cells have a unique epigenetic signature. Genome Res (2006) 2.89

Cost-effectiveness of Mohs Micrographic Surgery vs Surgical Excision for Basal Cell Carcinoma of the Face. Arch Dermatol (2006) 2.84

Looking forward, looking back: assessing variations in hospital resource use and outcomes for elderly patients with heart failure. Circ Cardiovasc Qual Outcomes (2009) 2.80

Warfarin reversal: consensus guidelines, on behalf of the Australasian Society of Thrombosis and Haemostasis. Med J Aust (2004) 2.74

Facts and fiction of poor compliance as a cause of inadequate blood pressure control: a systematic review. J Hypertens (2004) 2.71

Progression from paroxysmal to persistent atrial fibrillation clinical correlates and prognosis. J Am Coll Cardiol (2010) 2.59

Low molecular weight heparin and aspirin for recurrent pregnancy loss: results from the randomized, controlled HepASA Trial. J Rheumatol (2009) 2.58

An update of consensus guidelines for warfarin reversal. Med J Aust (2013) 2.41

Safe exclusion of pulmonary embolism using the Wells rule and qualitative D-dimer testing in primary care: prospective cohort study. BMJ (2012) 2.38

Comparing the diagnostic performance of 2 clinical decision rules to rule out deep vein thrombosis in primary care patients. Ann Fam Med (2011) 2.34

The incidence of recurrent venous thromboembolism after treatment with vitamin K antagonists in relation to time since first event: a meta-analysis. Arch Intern Med (2003) 2.33

Diagnostic strategies for excluding pulmonary embolism in clinical outcome studies. A systematic review. Ann Intern Med (2003) 2.33

Venous thromboembolism prophylaxis in acutely ill hospitalized medical patients: findings from the International Medical Prevention Registry on Venous Thromboembolism. Chest (2007) 2.32

The effect of low molecular weight heparin on survival in patients with advanced malignancy. J Clin Oncol (2005) 2.31

Intraocular pressure-lowering effects of all commonly used glaucoma drugs: a meta-analysis of randomized clinical trials. Ophthalmology (2005) 2.30

Oral thrombin inhibitor dabigatran etexilate vs North American enoxaparin regimen for prevention of venous thromboembolism after knee arthroplasty surgery. J Arthroplasty (2008) 2.30

Clinical utility of D-dimer in patients with suspected pulmonary embolism and nondiagnostic lung scans or negative CT findings. Chest (2004) 2.30

Enoxaparin followed by once-weekly idrabiotaparinux versus enoxaparin plus warfarin for patients with acute symptomatic pulmonary embolism: a randomised, double-blind, double-dummy, non-inferiority trial. Lancet (2011) 2.24

Oral rivaroxaban versus standard therapy for the treatment of symptomatic venous thromboembolism: a pooled analysis of the EINSTEIN-DVT and PE randomized studies. Thromb J (2013) 2.21

Do antifibrinolytics reduce allogeneic blood transfusion in orthopedic surgery? Anesthesiology (2006) 2.18

Safely ruling out deep venous thrombosis in primary care. Ann Intern Med (2009) 2.16

Clinical features of paediatric pulmonary hypertension: a registry study. Lancet (2012) 2.13

Triiodothyronine levels in athyreotic individuals during levothyroxine therapy. JAMA (2008) 2.10

Assessment of an age-adjusted warfarin initiation protocol. Ann Pharmacother (2003) 2.10

Rivaroxaban: population pharmacokinetic analyses in patients treated for acute deep-vein thrombosis and exposure simulations in patients with atrial fibrillation treated for stroke prevention. Clin Pharmacokinet (2011) 2.09

Quality of life in the Canadian Implantable Defibrillator Study (CIDS). Am Heart J (2002) 2.09

Extended prophylaxis of venous thromboembolism with fondaparinux in patients undergoing major orthopaedic surgery in Italy: a cost-effectiveness analysis. Intern Emerg Med (2009) 2.03

Selective testing for thrombophilia in patients with first venous thrombosis: results from a retrospective family cohort study on absolute thrombotic risk for currently known thrombophilic defects in 2479 relatives. Blood (2009) 1.93

Sex-based differences in the effect of intra-arterial treatment of stroke: analysis of the PROACT-2 study. Stroke (2006) 1.86

Effect of amiodarone and sotalol on ventricular defibrillation threshold: the optimal pharmacological therapy in cardioverter defibrillator patients (OPTIC) trial. Circulation (2006) 1.86

Antithrombotic treatment in real-life atrial fibrillation patients: a report from the Euro Heart Survey on Atrial Fibrillation. Eur Heart J (2006) 1.84

Extended prophylaxis of venous thromboembolism with idraparinux. N Engl J Med (2007) 1.84